# About KLOW Direct | KLOW peptide

> About KLOW Direct: an independent editorial project that publishes plain-English, cited summaries of the research literature on the KLOW peptide blend. Not a clinic, not a vendor.

An independent editorial reading room for the four-peptide KLOW research record.

## What this site is

KLOW Direct is an independent editorial project that publishes summaries of the peer-reviewed research literature on the KLOW peptide blend and its four components — KPV, GHK-Cu, BPC-157 and TB-500. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "direct" in our name describes how we read the literature — plainly, and straight to the source — not a service we offer. It is an editorial posture, a position the publisher takes relative to the research, and nothing more. There is no dispensary behind this page, no order desk, and no consultation.

## How we read the evidence

KLOW is an unusual subject because it is a blend, not a molecule, and the blend has never been studied. We treat that honestly. Every finding on this site is attributed to the single peptide it actually concerns, and the absence of any combination study is stated plainly rather than papered over. Where the strongest data are for full-length thymosin beta-4 and not the short TB-500 fragment, we say so.

We lead with what the component studies measured, attribute after, and cite every quantitative claim to a source with a DOI or PubMed link. We do not recommend doses, we do not give medical guidance, and we keep community reports clearly separated from cited research and labeled as anecdotal. The goal is a clear, accurate map of what is known, what is reported, and where the road runs out.

## What we do not do

We do not sell, supply, or source the KLOW blend or any of its components. We do not tell anyone to use it, and we do not provide protocols, dosing instructions, or clinical advice. We do not present anecdote as evidence. None of the four peptides is FDA-approved for human use, and TB-500/thymosin beta-4 is on the WADA Prohibited List — facts we state where they matter rather than burying. This is a reading room, not a pharmacy and not a clinic.

---

A gilded reading room for the four-peptide KLOW record — KPV, GHK-Cu, BPC-157 and TB-500 each set in its own porcelain panel and weighed against its own studies, the gold reserved for what the literature actually measured and the blend's panel left elegantly empty because no controlled trial has filled it; no clinic behind the scrollwork and nothing here dispensed or sold.